Valuation: Alligator Bioscience AB

Market Cap 13.13M 1.31M 1.16M 1.09M 992K 1.86M 126M 1.88M 5.06M 64.22M 4.92M 4.81M 207M P/E 2026 *
-
P/E 2027 * -
Enterprise Value 13.13M 1.31M 1.16M 1.09M 992K 1.86M 126M 1.88M 5.06M 64.22M 4.92M 4.81M 207M EV / Sales 2026 *
2.22x
EV / Sales 2027 * 0.26x
Free-Float
83.58%
Yield 2026 *
-
Yield 2027 * -
1 week 0.03
Extreme 0.033
0.04
1 month 0.03
Extreme 0.033
0.04
Current year 0.03
Extreme 0.033
0.04
1 year 0.03
Extreme 0.033
0.04
3 years 0.03
Extreme 0.033
0.04
5 years 0.03
Extreme 0.033
0.04
10 years 0.03
Extreme 0.033
0.04
Manager TitleAgeSince
Chief Executive Officer 55 31/05/2021
Director of Finance/CFO 61 11/08/2024
Chief Tech/Sci/R&D Officer - 31/03/2025
Director TitleAgeSince
Chairman 55 -
Director/Board Member 64 31/05/2021
Director/Board Member 68 08/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
-1.56%+8.29% - - 1.31M
-0.70%-4.28%+52.62%+86.42% 71.53B
-0.35%+1.17%+37.01%+81.07% 60.12B
-1.23%+2.78%+9.52%+37.31% 48.85B
+1.23%+1.04%+42.49%+39.60% 44.28B
+2.39%+8.78%+344.30%+692.85% 43.83B
+1.75%+1.79%+9.05%+108.14% 41.53B
+0.34%+0.22%+5.18%+47.36% 30.13B
+4.77%+6.46%+41.54%+22.78% 27.98B
-0.32%-3.68%-20.85%+349.27% 25.25B
Average +0.64%-0.06%+57.87%+162.76% 43.72B
Weighted average by Cap. +0.61%-0.16%+62.50%+153.43%

Financials

2026 *2027 *
Net sales 5.9M 589K 520K 492K 446K 836K 56.52M 844K 2.27M 28.86M 2.21M 2.16M 92.88M 49.7M 4.96M 4.38M 4.14M 3.76M 7.04M 476M 7.11M 19.15M 243M 18.63M 18.23M 782M
Net income -15.2M -1.52M -1.34M -1.27M -1.15M -2.15M -146M -2.18M -5.86M -74.35M -5.7M -5.57M -239M 28.9M 2.89M 2.55M 2.41M 2.18M 4.1M 277M 4.14M 11.14M 141M 10.83M 10.6M 455M
Net Debt - -
Logo Alligator Bioscience AB
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
Employees
11
Date Price Change Volume
30/09/26 SEK 0.0379 -1.56% 408,689
29/09/26 SEK 0.0385 0.00% 960,059
28/09/26 SEK 0.0385 +10.63% 1,755,516
25/09/26 SEK 0.0348 -3.33% 1,960,524
24/09/26 SEK 0.0360 +2.86% 3,019,670

Annual profits - Rate of surprise